Core Viewpoint - The global ESG investment is accelerating towards mainstream adoption, with investors recognizing that companies with strong ESG performance tend to have better innovation capabilities and long-term resilience, leading to more stable and sustainable investment returns [1] Group 1: Medical Aesthetics Business Growth - The medical aesthetics business of the company is experiencing explosive growth, with projected revenue of 744 million yuan in 2024, representing a year-on-year increase of 65.4% [3] - The growth is supported by continuous investment in product innovation compliance and channel deepening [3] Group 2: Product Innovation and Quality - The company has developed a product matrix for medical aesthetics, including self-developed injectable products that have received regulatory approval, focusing on quality stability, clinical efficacy, and safety [4] - The company is expanding its product line with potential new products expected to be approved in the next 1 to 3 years, including collagen and water light needles [4] Group 3: Channel Expansion and Internationalization - The company has established a dual-track model of "direct sales + agency," covering over 370 cities and collaborating with more than 6,200 medical aesthetic institutions [6] - The company is accelerating its international expansion, with successful registrations of some products in Indonesia and Malaysia, and plans to enter markets in Brazil and the Middle East [6] Group 4: Innovation in Pharmaceuticals - The company is recognized for its deep engagement in innovative drugs and biopharmaceuticals, focusing on improving drug accessibility and addressing unmet clinical needs [7] - The company has multiple innovative drugs approved for various therapeutic areas, including oncology and diabetes, with significant market potential [12] Group 5: Financial Outlook and Growth Strategy - The company aims to achieve approximately 2.3 billion yuan in revenue by 2025, with a goal of turning overall operating profit positive [13] - With a cash reserve of nearly 4 billion yuan, the company is well-positioned to support the commercialization of its new products and drive further value enhancement [13]

Investment Rating - The report assigns a positive investment rating to the company, indicating a favorable outlook for its growth and performance in the market [4]. Core Insights - The company has successfully transitioned from an online medical beauty platform to a physical service entity, marking a significant strategic shift towards vertical integration in the industry [6][4]. - As of June 30, 2025, the company operates 31 clinics, making it the largest light medical beauty chain in China, with its chain business becoming the largest revenue contributor [4]. - The company aims to expand its clinic network to 1,000 locations by the end of 2025, focusing on high-value markets in major cities [7]. Summary by Sections Recent Performance - The company's stock has shown impressive growth, with a 239.21% increase over the past month and a 234.25% increase over the past year, significantly outperforming the S&P 500 [3]. - As of July 3, 2025, the company's market capitalization stands at $325.73 million [3]. Business Transformation - The company has shifted its focus from online services to offline medical beauty services, responding to competition from platforms like Alibaba Health and Meituan [6]. - The first self-operated clinic opened in May 2023, and the company has since established strategic partnerships to enhance its service offerings [6]. Financial Performance - In Q1 2025, the company reported revenues of 297 million yuan, with a notable 551.4% increase in medical beauty treatment service revenue [7]. - The company anticipates Q2 2025 medical beauty treatment service revenues to reach between 120 million and 140 million yuan, reflecting a substantial year-over-year growth [7]. Operational Efficiency - The company has implemented digital tools to enhance operational efficiency, including management systems and customer engagement platforms [7]. - The average monthly revenue per clinic reached 4.7 million yuan, with a profit margin of 17% [7].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market during the week of June 27 to July 4, 2025, with the Shenwan Beauty Care Index declining by 0.6% and the Shenwan Cosmetics Index down by 1.5% [3][4]. - Domestic brands such as Maogeping and others showed significant growth, with some achieving over 50% growth in June, which is expected to positively impact Q2 performance [3][9]. - The report highlights a strong performance from leading domestic brands during the 618 shopping festival, with a notable increase in sales momentum post-event [9][10]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index decreased by 0.6%, while the Shenwan Cosmetics Index fell by 1.5%, indicating weaker performance compared to the Shenwan A Index [4]. - The personal care products index saw a slight increase of 0.7%, but still lagged behind the Shenwan A Index by 0.4% [4]. Key Company Performance - Expected performance for major companies in Q2 includes: - Upbeauty: Revenue and net profit expected to grow by 16% and 25% respectively [11]. - Marubi: Anticipated revenue and net profit growth of 22% and 28% [11]. - Proya: Projected revenue and net profit growth of 10% and 15% [11]. - Maogeping: Expected revenue and net profit growth of 38% and 35% [11]. - Ruifeng: Anticipated growth of 70% and 75% in revenue and net profit respectively [11]. - Juzhibio: Expected growth of 25% and 20% in revenue and net profit [11]. Market Trends - The report notes a robust recovery in consumer demand, with a 4.1% year-on-year increase in retail sales for cosmetics in the first five months of 2025 [20]. - The domestic market is seeing a shift with local brands gaining market share, as evidenced by the performance of brands like Proya and Maogeping during major shopping events [34]. Investment Recommendations - Recommended stocks include: - Upbeauty, Proya, and Marubi for their comprehensive brand matrices and growth potential [15]. - Maogeping and Juzhibio for their strong positioning in niche markets [15]. - Attention is advised for Shanghai Jahwa, Betaini, and Huaxi Biological for potential growth [15]. E-commerce Insights - Data from Douyin indicates significant growth for domestic brands, with Han Shu achieving a GMV of 7.2 billion yuan, reflecting a 53% year-on-year increase [16]. - The overall GMV for domestic brands in June reached over 50% growth, indicating a strong market presence [9][16].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the rapid development of the "New Oxygen Youth Clinic" and the significant changes in the shareholding structure of "Beautiful Garden" following the exit of major shareholder CPE [5][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [8][29] Summary by Sections Retail Market Overview - The retail industry index closed at 2152.72 points, down 0.16%, underperforming the Shanghai Composite Index which rose by 1.40% [7][14] - The retail sector has seen a decline of 3.85% year-to-date [14][17] Industry Dynamics - CPE plans to sell approximately 51.33 million shares (about 21.77%) of "Beautiful Garden," leading to a significant change in the company's shareholding structure [5][24] - "New Oxygen" has transformed from an online platform to a chain of clinics, with a 551% year-on-year increase in revenue for its chain business in Q1 2025 [5][27] Investment Recommendations - Investment Theme 1: Focus on differentiated product capabilities and consumer insights in the gold and jewelry sector, recommending companies like "Old Shop Gold," "Chao Hong Ji," and "Zhou Dafu" [8][29] - Investment Theme 2: Emphasize retail companies that actively adapt to trends, recommending "Yonghui Supermarket" and "Aiying Room" [8][29] - Investment Theme 3: Highlight domestic beauty brands with strong differentiation, recommending "Mao Ge Ping," "Po Lai Ya," and "Shang Mei" [8][30] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers, recommending "Ai Mei Ke" and "Ke Di-B" [8][30] Company-Specific Insights - "Zhou Dafu" reported a revenue of 896.56 million HKD for FY2025, down 17.5%, with a focus on improving product structure and store quality [36][37] - "Old Shop Gold" achieved a revenue of 8.506 billion CNY for FY2024, up 167.5%, with a strong brand expansion strategy [31][32] - "Chao Hong Ji" reported a revenue of 2.252 billion CNY in Q1 2025, up 25.4%, driven by differentiated product offerings [39][40] - "Zhou Da Sheng" faced revenue pressure with a 47.3% decline in Q1 2025, but future growth potential is anticipated through brand optimization [42]

Core Insights - Japan's beauty medical industry has reached a market size of approximately 594 billion yen, surpassing South Korea to become the new "cosmetic powerhouse" [2] - The growth of Japan's medical beauty market has been significant, with a 120% increase in 2021 and a continued rise in demand for various treatments [3] - Male consumers have become a major driving force in the industry, with the number of male clients increasing 16 times over the past decade [4] Market Growth - The medical beauty market in Japan expanded 2.39 times from 2009 to 2023, indicating a robust growth trajectory [4] - In 2023, the market size reached over 500 billion yen, reflecting a growth of 108.8% compared to the previous year [3] Consumer Behavior - Approximately 70% of surveyed men express concern about their appearance, with 43% considering some form of beauty medical treatment [5] - The pressure of workplace competition and the desire for self-confidence are significant motivators for men seeking cosmetic procedures [5][6] Economic Context - Japan's employment rate for new graduates reached a historic high of 98.1% in 2024, but the country faces a demographic challenge with a declining birth rate and an increasing death rate [5] - The economic downturn has led individuals to invest in their appearance as a strategy to enhance job security and competitiveness [9] Industry Comparison - Japan's medical beauty culture is evolving, with a notable increase in public acceptance and participation in cosmetic procedures [11] - The country aspires to replicate South Korea's successful model of integrating medical beauty with tourism and consumption, although challenges remain [12][13] Regulatory Environment - Japan's medical beauty industry currently lacks stringent regulatory oversight, leading to a rise in complications from procedures performed by non-specialist doctors [19] - The increase in reported complications highlights the need for improved regulatory measures to ensure patient safety [19] Investment Trends - Global beauty companies are increasingly investing in the medical beauty sector, with major brands like L'Oréal and Estée Lauder expanding their offerings [21][22] - Despite the growth potential, there are concerns about the sustainability of the medical beauty market, as evidenced by declining average spending per customer and increased competition [27]

Group 1 - The core event involves the investment of 3.4 billion yuan by Zhong Shanshan, the richest man in China, into Jinbo Biological, making him the second-largest shareholder [2] - Jinbo Biological announced plans to raise 2 billion yuan by issuing shares to Yang Xia, the actual controller, who will transfer shares worth 1.403 billion yuan to Hangzhou Jiushi, both controlled by Zhong Shanshan [2][6] - The investment comes amid declining performance for Zhong's companies, Nongfu Spring and Wantai Biological, which faced significant revenue and profit drops in 2024 [4][5] Group 2 - The Chinese recombinant collagen market is projected to grow rapidly, reaching 58.57 billion yuan by 2025, with a compound annual growth rate of 44.93% until 2030 [6] - Jinbo Biological is unique in the market, being the only company with a full range of products including freeze-dried fibers and injectable recombinant collagen, and has shown impressive growth from 233 million yuan in revenue in 2021 to 1.443 billion yuan in 2024 [7] - The company's gross profit margin has increased from 82.29% to 92.02%, surpassing that of Guizhou Moutai, earning it the nickname "the Moutai for women" [7][8] Group 3 - Jinbo Biological's sales of medical devices reached 1.254 billion yuan in 2024, a growth of 84.37%, with its flagship product contributing over 1 billion yuan in revenue [7] - The partnership is seen as a strategic move for both parties, with Jinbo seeking to leverage Zhong's extensive retail network of over 3 million outlets to expand its market reach [8][9] - The collaboration is viewed as a potentially win-win situation, although the long-term outcomes remain to be seen [9]

Core Viewpoint - The A-share market has regained upward momentum in July, supported by a low interest rate environment and a recovery in risk appetite, with expectations for incremental policies to potentially break the current sideways trend [1][2]. Group 1: Market Overview - After breaking through the March high, the A-share market experienced slight fluctuations but continued to trend upwards, reaching recent highs [1]. - The market's risk appetite has improved, with sectors like non-bank financials, media, and military industry showing signs of recovery [1]. - The upcoming policy window in July is expected to further support the market's gradual upward trajectory [1]. Group 2: Sector Analysis - The market is likely to see a thematic event-driven approach in July, with a high probability of sector rotation between high and low-performing areas [2]. - Key sectors to watch include: 1. Consumer expansion and domestic demand, with a focus on dairy products, IP consumption, leisure tourism, and medical aesthetics [2]. 2. Robotics, with a trend towards domestic production and integration into daily life, particularly in humanoid and functional robots [2]. 3. Semiconductor localization, emphasizing semiconductor equipment, wafer manufacturing, materials, and IC design [2]. 4. Military industry, with expectations for order recovery and signs of bottoming out in Q1 reports across various sub-sectors [2]. 5. Innovative pharmaceuticals, which are expected to reach a turning point in fundamentals after a prolonged adjustment period [2]. Group 3: Market Performance - The A-share market has shown a continued upward trend, with electronic and other high-elasticity sectors leading the gains [3]. - Despite some fluctuations, the overall market confidence has strengthened, with over 3,200 stocks rising, indicating a positive earning effect [3]. - Leading sectors included electronics, power equipment, and pharmaceuticals, while sectors like coal, transportation, and banking faced declines [3].

Summary of the Conference Call for Meili Tianyuan Company Overview - **Company**: Meili Tianyuan - **Industry**: Health and Beauty, specifically focusing on wellness, beauty care, and medical aesthetics Key Points and Arguments Financial Performance - In the first half of 2025, Meili Tianyuan's overall operations met expectations, with both equity capital and net consumer traffic increasing by approximately 20% [2][5] - The sub-sector of sub-health showed outstanding performance with a year-on-year growth of 50% [2][5] - The beauty and health business grew by 20%, while the medical aesthetics business grew by 10%, primarily driven by offline customer traffic [2][5] - The company is confident in achieving its annual revenue target of 2 billion and profit target of 320 million [2][6][7] Business Strategy - The company will not adjust its annual performance expectations and anticipates a 30%-40% growth in the sub-health business [2][8] - The store opening strategy is "one city, one store," focusing on beauty and health memberships, with stable store numbers but increased single-store efficiency through upgrades and expansions [2][9] - Meili Tianyuan aims to enhance its net profit margin by 0.5 percentage points through supply chain optimization, digitalization, and backend cost reduction [2][11] Profitability Metrics - The gross margin for the beauty and health business is approximately 30%, with an operating profit margin of 5%-10% [2][11] - The medical aesthetics business has a gross margin exceeding 50% and an operating profit margin close to 40% [2][11] - The sub-health business has recently surpassed a gross margin of 50%, with potential to align with medical aesthetics in the future [2][11] Market Position and Growth - Currently, the market share is about 0.04%, and the company plans to increase this through organic growth, store openings, membership expansion, and mergers and acquisitions [3][14] - Meili Tianyuan has become a leader in the chain industry, having acquired a top-five player, Nairui, in 2024 [13][14] Shareholder Changes - A significant shareholder, CPE, has exited, transferring shares to other core institutional shareholders, which has improved liquidity and resolved previous low trading volume issues [4][12] Future Plans - The company is optimistic about its long-term growth and plans to continue integrating and optimizing Nairui's operations [15][21] - Future acquisitions will focus on high-quality suppliers and compatible brands that align with customer profiles [21][23] Marketing and Customer Engagement - Meili Tianyuan has three major promotional events planned for the year, with a focus on overall growth rather than individual events [27] - Customer traffic has increased across all segments, with new product launches contributing to revenue growth [28] Brand Positioning - The company is viewed as an attractive growth-oriented chain in the market, with stable growth reinforcing brand strength [29] Additional Important Information - The company is currently meeting the turnover rate requirements for the Hong Kong Stock Connect and is working towards meeting market capitalization coverage requirements [12] - The average spending per visit in the medical aesthetics sector is around 30,000 yuan, with customers visiting three to four times a year [25]

Investment Rating - The industry rating is "Outperform the Market" [3] Core Viewpoints - The strategic transformation of China Resources from "holding integration" to "ecological leadership" is highlighted, focusing on the integration of research and development capabilities with channel strengths in the medical beauty sector [1][5] - The partnership between Shanghai Haohai Biological Technology Co., Ltd. and China Resources Pharmaceutical Group aims to explore new opportunities in the Chinese medical beauty industry by leveraging their combined strengths [1][2] Summary by Sections Industry Dynamics - The report discusses the shift in China Resources' strategy since 2018, moving from traditional acquisitions to a dual-driven model of "capital + industry," emphasizing ecological integration and reducing purely financial mergers [1][5] - The collaboration with Haohai Biological is positioned as a significant step in establishing a closed-loop ecosystem in the medical beauty field, integrating technology research, clinical transformation, and market promotion [5] Company Analysis - Haohai Biological is recognized for its strong R&D and production capabilities, particularly in hyaluronic acid products, and has established a leading position in various medical fields including ophthalmology and aesthetic medicine [2][6] - The company has successfully launched innovative products, such as the fourth-generation organic cross-linked hyaluronic acid, which is the only one in China using lysine as a cross-linking agent [6] Market Positioning - Haohai Biological has built long-term relationships with thousands of hospitals and medical beauty chains across China, while China Resources has a vast distribution network covering over 28 provinces and municipalities, enhancing market penetration and operational efficiency [7] - The report suggests that the collaboration will accelerate the clinical value transformation of Haohai's core products and improve sales efficiency [7] Investment Recommendations - The report recommends focusing on companies within the China Resources ecosystem that are expected to show improved performance in the upcoming interim reports, as well as those benefiting from state-owned enterprise reforms [7]

Group 1 - The consumer industry is undergoing a profound transformation from scale expansion to quality upgrading, driven by policy incentives, technological iterations, and changes in consumer preferences and habits [1][14]. - The new consumer groups represented by Generation Z, the elderly, and women are pushing consumption demand towards personalization and quality [1][17]. - Domestic brands are experiencing sustained growth, with sensory experiences becoming the core touchpoint linking consumers and products [1][29]. Group 2 - The importance of domestic demand has been reaffirmed, with a shift in focus from short-term demand stimulation to systematically enhancing consumer willingness, supported by policies such as employment and entrepreneurship initiatives [2][50]. - From January to May 2025, the total retail sales of consumer goods increased by 5.0% year-on-year, indicating a recovery in domestic demand [2]. Group 3 - Four major consumption trends are identified: the rise of domestic brands, emotional consumption, the silver economy, and AI+ consumption [3][4]. - The silver economy is driven by an aging population, with the proportion of individuals aged 65 and above exceeding 14% in 2021, and expected to surpass 30% by 2035 [21][23]. - Emotional consumption is characterized by a shift from functional to self-rewarding and social value, with consumers willing to pay for emotional value [3][20]. Group 4 - The report recommends focusing on structural opportunities in the consumer sector, highlighting four core investment themes: the rise of domestic brands, high-growth emotional consumption, the burgeoning silver economy, and AI+ consumption [4][18]. - Specific companies are recommended for investment, including domestic brands like Lao Pu Gold, Shangmei Co., and Midea, as well as emotional consumption leaders like Pop Mart and Heytea [5][4]. Group 5 - The integration of AI into the consumer chain is emphasized, with a focus on companies that demonstrate strong product innovation capabilities [3][4]. - The rise of online sales driven by live streaming and e-commerce is reshaping the retail landscape, with online retail sales reaching 6.0 billion in the first five months of 2025, reflecting an 8.5% year-on-year growth [41][40]. Group 6 - The sensory experience is becoming a core value of brands, with consumers increasingly demanding high-quality sensory interactions [32][39]. - The marketing landscape is shifting towards decentralized models, with KOL and KOC marketing gaining prominence, allowing brands to achieve precise targeting and higher ROI [49][40].